New treatments for acute humoral rejection of kidney allografts (Q36802609)

16 August 2017

1 reference

title

New treatments for acute humoral rejection of kidney allografts (English)

1 reference

16 August 2017

Jean-Pierre Venetz

1

1 reference

PubMed ID

17461736

16 August 2017

Manuel Pascual

series ordinal

2

1 reference

PubMed ID

17461736

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

5

1 reference

16 August 2017

625-633

1 reference

Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Humoral rejection of organ allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

An association between antibodies specific for endothelial cells and renal transplant failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Plasmapheresis as rescue therapy in accelerated acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Predicting kidney graft failure by HLA antibodies: a prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Overcoming a positive crossmatch in living-donor kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Tacrolimus rescue therapy for renal allograft rejection--five-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Epratuzumab in the therapy of oncological and immunological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

B cell targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.625

10.1517/13543784.16.5.625

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17461736